AccessibilityHelpAbout Us
StageZero Life Sciences logo

StageZero Life Sciences(OTC) SZLSF

Market Cap$123.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 Year-100%
1 Year-96%
1 Month-80%
$0.00
+0.00%
+0.00Today
StageZero Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-27
StageZero Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-06
1 month-80.39%USD 0.012026-03-24
3 month-80.39%USD 0.012026-03-24
Year to date+100%USD 0.002025-12-18
1 year-95.61%USD 0.022025-07-02
3 year-97.89%USD 0.052023-07-28
5 year-99.72%USD 0.362021-07-28
Since inception-99.99%USD 9.602011-10-12

StageZero Life Sciences Financials at a Glance

Market Cap

$123.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.15M

Net Income (TTM)

-$2.26M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.62 (Low)

Price

$0.00

Volume

208

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Sep 10, 2026

SZLSF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About StageZero Life Sciences

StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise focused on developing and commercializing proprietary molecular diagnostic tests. These tests are designed for early disease detection and personalized health management, particularly in oncology, within the United States and Canada.

Products and Services
  • Aristotle: A multi-cancer panel test screening multiple cancer types from a single blood sample
  • ColonSentry: A blood test assessing colorectal cancer risk
  • BreastSentry: A test determining a woman's risk of developing breast cancer
Growth Outlook
  • Expansion into personalized health management is expected to drive future revenue growth
  • Increased focus on oncology-related diagnostics aligns with market trends
  • Potential partnerships could enhance product distribution and market reach
Financial Highlights
  • Recent quarterly revenue of $499,663 shows a sequential increase from $390,083
  • Trailing twelve months (TTM) revenue of $1,399,635 indicates growth potential
  • Operating expenses remain high, reflecting ongoing investment in product development
StageZero Life Sciences Ltd. operates in the medical diagnostics and research industry, leveraging its proprietary Sentinel Principle platform technology to identify novel biomarkers from whole blood samples. The company’s lead product, Aristotle, showcases its innovative approach to cancer detection, emphasizing high sensitivity and specificity. The product portfolio also includes tests for colorectal and breast cancer, as well as COVID-19 PCR testing. The growth outlook for StageZero is promising, driven by an increasing emphasis on personalized health management and oncology diagnostics. The company is well-positioned to capitalize on market trends, with potential partnerships that could further enhance its distribution capabilities. Financially, the company has shown a recent uptick in revenue, with the latest quarterly figures indicating a positive trend. However, operating expenses remain a significant factor, reflecting the company's commitment to research and development. Investors may find interest in the company's strategic direction and its potential to capture a larger share of the diagnostics market.
AI Generated • Aug 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

40

CEO

James R. Howard-Tripp

Website

www.stagezerolifesciences.com

Headquarters

Richmond Hill, ON L4B 3B2, CA

SZLSF Financials

Key Financial Metrics (TTM)

Gross Margin

-10.64%

Operating Margin

-204.13%

Net Income Margin

-300.79%

Return on Equity

481.50%

Return on Capital

N/A

Return on Assets

-1629.25%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$123.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

123.55M

Volume

208

Avg. Volume

7.27

Financials (TTM)

Gross Profit

$387.64K

Operating Income

-$2.12M

EBITDA

-$1.96M

Operating Cash Flow

-$97.37K

Capital Expenditure

-$0.04

Free Cash Flow

-$97.37K

Cash & ST Invst.

$15.03K

Total Debt

$2.13M

StageZero Life Sciences Performance Analysis

StageZero Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 5,068,156N/A
20222022-12-31USD 3,795,076-25.1%
StageZero Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30-6.0%
Q12024-03-31N/A
Q22024-06-30-24.9%
Q32024-09-3028.1%
StageZero Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.11N/A
20222022-12-31USD -0.118.5%
StageZero Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30-103.0%
Q12024-03-31N/A
Q22024-06-30-71.0%
Q32024-09-3037.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$499.66K

-37.0%

Gross Profit

-$69.60K

-157.3%

Gross Margin

-13.93%

N/A

Market Cap

$123.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.09K

N/A

Employees

40

N/A

Net Income

-$399.28K

+0.6%

EBITDA

-$337.00K

-39.7%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$15.03K

-76.6%

Total Debt

$2.13M

+44.0%

Accounts Receivable

$92.68K

+21.9%

Inventory

$52.09K

-37.2%

Long Term Debt

$1.00M

+41.1%

Short Term Debt

$1.13M

+46.7%

Return on Assets

-16.29%

N/A

Return on Invested Capital

1.22%

N/A

Free Cash Flow

$10.26K

+45.4%

Operating Cash Flow

$10.26K

+45.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MJARFMJardin Group, Inc.
$0.00+0.00%
IDTAIDenta Corp.
$0.36+0.00%
IVROInVitro International
$0.07-7.00%
EXMTAnything Technologies Media, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TNONTenon Medical
$5.30+1.17%
SPCXSpace Exploration Technologies
$148.18+0.00%
NVDANvidia
$218.36-0.02%
INTCIntel
$100.32-0.06%

Questions About SZLSF

What is the current price of StageZero Life Sciences?

StageZero Life Sciences is trading at $0.00 per share.

What is the 52-week range for StageZero Life Sciences?

Over the past 52 weeks, StageZero Life Sciences has traded between $0.00 and $0.01.

How much debt does StageZero Life Sciences have?

As of the most recent reporting period, StageZero Life Sciences reported total debt of $2.09M.

How much cash does StageZero Life Sciences have on hand?

StageZero Life Sciences reported $15.03K in cash and cash equivalents in its most recent financial results.

What is StageZero Life Sciences’s dividend yield?

StageZero Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services